114 related articles for article (PubMed ID: 25630658)
1. miR-204 is dysregulated in metastatic prostate cancer in vitro.
Todorova K; Metodiev MV; Metodieva G; Zasheva D; Mincheff M; Hayrabedyan S
Mol Carcinog; 2016 Feb; 55(2):131-47. PubMed ID: 25630658
[TBL] [Abstract][Full Text] [Related]
2. Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.
Todorova K; Metodiev MV; Metodieva G; Mincheff M; Fernández N; Hayrabedyan S
Horm Cancer; 2017 Feb; 8(1):28-48. PubMed ID: 28050800
[TBL] [Abstract][Full Text] [Related]
3. Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis.
Saini S; Majid S; Yamamura S; Tabatabai L; Suh SO; Shahryari V; Chen Y; Deng G; Tanaka Y; Dahiya R
Clin Cancer Res; 2011 Aug; 17(16):5287-98. PubMed ID: 21159887
[TBL] [Abstract][Full Text] [Related]
4. The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer.
Hart M; Wach S; Nolte E; Szczyrba J; Menon R; Taubert H; Hartmann A; Stoehr R; Wieland W; Grässer FA; Wullich B
FEBS J; 2013 May; 280(9):2105-16. PubMed ID: 23480797
[TBL] [Abstract][Full Text] [Related]
5. MiR-129 inhibits cell proliferation and metastasis by targeting ETS1 via PI3K/AKT/mTOR pathway in prostate cancer.
Xu S; Ge J; Zhang Z; Zhou W
Biomed Pharmacother; 2017 Dec; 96():634-641. PubMed ID: 29035829
[TBL] [Abstract][Full Text] [Related]
6. miR-377 functions as a tumor suppressor in human clear cell renal cell carcinoma by targeting ETS1.
Wang R; Ma Y; Yu D; Zhao J; Ma P
Biomed Pharmacother; 2015 Mar; 70():64-71. PubMed ID: 25776481
[TBL] [Abstract][Full Text] [Related]
7. Regulation of the MIR155 host gene in physiological and pathological processes.
Elton TS; Selemon H; Elton SM; Parinandi NL
Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
[TBL] [Abstract][Full Text] [Related]
8. Myeloid zinc-finger 1 (MZF-1) suppresses prostate tumor growth through enforcing ferroportin-conducted iron egress.
Chen Y; Zhang Z; Yang K; Du J; Xu Y; Liu S
Oncogene; 2015 Jul; 34(29):3839-47. PubMed ID: 25284586
[TBL] [Abstract][Full Text] [Related]
9. miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT.
Kao CJ; Martiniez A; Shi XB; Yang J; Evans CP; Dobi A; deVere White RW; Kung HJ
Oncogene; 2014 May; 33(19):2495-503. PubMed ID: 23728339
[TBL] [Abstract][Full Text] [Related]
10. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer.
Zhang Y; Yan LX; Wu QN; Du ZM; Chen J; Liao DZ; Huang MY; Hou JH; Wu QL; Zeng MS; Huang WL; Zeng YX; Shao JY
Cancer Res; 2011 May; 71(10):3552-62. PubMed ID: 21444677
[TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence.
Hagen RM; Adamo P; Karamat S; Oxley J; Aning JJ; Gillatt D; Persad R; Ladomery MR; Rhodes A
Am J Clin Pathol; 2014 Oct; 142(4):533-40. PubMed ID: 25239421
[TBL] [Abstract][Full Text] [Related]
12. Nitric Oxide Up-Regulates RUNX2 in LNCaP Prostate Tumours: Implications for Tumour Growth In Vitro and In Vivo.
Nesbitt H; Browne G; O'Donovan KM; Byrne NM; Worthington J; McKeown SR; McKenna DJ
J Cell Physiol; 2016 Feb; 231(2):473-82. PubMed ID: 26189652
[TBL] [Abstract][Full Text] [Related]
13. Comparison of MAPK specificity across the ETS transcription factor family identifies a high-affinity ERK interaction required for ERG function in prostate cells.
Selvaraj N; Kedage V; Hollenhorst PC
Cell Commun Signal; 2015 Feb; 13():12. PubMed ID: 25885538
[TBL] [Abstract][Full Text] [Related]
14. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
[TBL] [Abstract][Full Text] [Related]
15. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
Ateeq B; Vellaichamy A; Tomlins SA; Wang R; Cao Q; Lonigro RJ; Pienta KJ; Varambally S
Prostate; 2012 Oct; 72(14):1542-9. PubMed ID: 22415461
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-1 and microRNA-499 downregulate the expression of the ets1 proto-oncogene in HepG2 cells.
Wei W; Hu Z; Fu H; Tie Y; Zhang H; Wu Y; Zheng X
Oncol Rep; 2012 Aug; 28(2):701-6. PubMed ID: 22664953
[TBL] [Abstract][Full Text] [Related]
17. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
[TBL] [Abstract][Full Text] [Related]
18. Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.
Kolar Z; Burdova A; Jamaspishvili T; Bouchal J; Kucerova R; Bienova M; Kral M; Student V
Neoplasma; 2014; 61(1):9-16. PubMed ID: 24195515
[TBL] [Abstract][Full Text] [Related]
19. ETS transcription factors and prostate cancer: the role of the family prototype ETS-1 (review).
Adler D; Wernert N
Int J Oncol; 2012 Jun; 40(6):1748-54. PubMed ID: 22366814
[TBL] [Abstract][Full Text] [Related]
20. ETS1 transcriptional activity is increased in advanced prostate cancer and promotes the castrate-resistant phenotype.
Smith AM; Findlay VJ; Bandurraga SG; Kistner-Griffin E; Spruill LS; Liu A; Golshayan AR; Turner DP
Carcinogenesis; 2012 Mar; 33(3):572-80. PubMed ID: 22232738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
